—
C+
C+ The full Closelook — membership. Open the C+ overview

BeiGene, Ltd. (ONC) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — BeiGene, Ltd.

ONC in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
BeiGene, now renamed BeOne Medicines AG, is an oncology company that discovers and develops cancer treatments across the United States, China and Europe. Its marketed products include a BTK inhibitor for blood cancers, a PD-1 antibody used in solid tumours and blood cancers, and separate treatments for Castleman disease and certain breast and solid-tumour cancers, alongside a wide clinical pipeline of compounds targeting different cancer pathways and partnerships with several other pharmaceutical firms.
Where it sits in the stack
BeiGene carries no seat in our index and sits outside the AI build-out stack the diary otherwise tracks. It belongs to the Healthcare sleeve of Closelook's universe, grouped by sector and country rather than by any layer of the build-out.
Who it is priced against
Closelook's peer group places it with other scored healthcare names in the same sector and country — argenx, Medpace, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals, Corcept Therapeutics and IDEXX Laboratories; the market also compares its PD-1 antibody against Merck's rival therapy.
Why Closelook tracks it
It carries a Closelook score, with momentum the strongest module and valuation the weakest; it holds no index seat and the diary has not yet quoted it.
What the diary watches
The diary watches whether clinical data from the pipeline compounds converts into approvals that could narrow the gap between the strong momentum read and the weaker valuation module.

BeiGene, Ltd. (ONC) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 63/100 composite (momentum 75, quality 63, valuation 32) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ONC, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against ONC on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What ONC pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +7.8% in FY2025 511 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in US: +1.8% week · −4.1% month · +13.2% quarter · +8.1% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is BeiGene, Ltd. (ONC)?

BeiGene, Ltd. trades as ONC on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is ONC in a Closelook index?

Not currently — BeiGene, Ltd. is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is BeiGene, Ltd.'s Closelook composite score?

63 out of 100, with momentum 75, quality 63 and valuation 32 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does ONC trade against its moving averages?

Uptrend stack intact: Trades +2.2% vs the 50-day and +10.3% vs the 200-day average, 8.9% below the 52-week high and +38.2% off the 52-week low; a golden cross printed 18 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does BeiGene, Ltd. do?

BeiGene, now renamed BeOne Medicines AG, is an oncology company that discovers and develops cancer treatments across the United States, China and Europe. Its marketed products include a BTK inhibitor for blood cancers, a PD-1 antibody used in solid tumours and blood cancers, and separate treatments for Castleman disease and certain breast and solid-tumour cancers, alongside a wide clinical pipeline of compounds targeting different cancer pathways and partnerships with several other pharmaceutical firms. Closelook's peer group places it with other scored healthcare names in the same sector and country — argenx, Medpace, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals, Corcept Therapeutics and IDEXX Laboratories; the market also compares its PD-1 antibody against Merck's rival therapy.

Where does BeiGene, Ltd. sit in the AI build-out?

BeiGene carries no seat in our index and sits outside the AI build-out stack the diary otherwise tracks. It belongs to the Healthcare sleeve of Closelook's universe, grouped by sector and country rather than by any layer of the build-out. It carries a Closelook score, with momentum the strongest module and valuation the weakest; it holds no index seat and the diary has not yet quoted it.

Does BeiGene, Ltd. pay a dividend?

No cash distribution shows in BeiGene, Ltd.’s price series over the last three years. The share count rose 7.8% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ONC, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.